Hemastatx brings innovation to patients with severe, underserved bleeding conditions. HMX-001 is a first-in-class anti-ADAMTS13 antibody targeting the root cause of severe bleeds in (rare) von Willebrand factor (VWF) disorders. Hemastatx is a KU Leuven spinoff and part of the BaseLaunch portfolio.

Biodelphis Therapeutics is a Swiss biotech startup, spinoff of EPFL. We developed a new generation of protease inhibitors with enhanced potency and safety, exhibiting all the qualities needed to become first-in-class drugs for the treatment of cancer, autoimmune diseases and bone diseases.

Enabling breakthrough medicines achieve the outcomes they were designed for. We unlock the full therapeutic potential of innovative drug candidates through our next-gen nanomedicine delivery platform. We want to establish our biovectors as the universal standard for targeted therapeutic delivery.